References

The International Classification of Diseases for Oncology, 4th Edition (ICD-O-4): an overview

10.1016/j.canep.2026.102989 · 2026 · External reference

A common classification framework for histone sequence alterations in tumours: an expert consensus proposal

10.1002/path.5666 · 2021 · External reference

Lipoblastoma-like tumor and fibrosarcoma-like lipomatous neoplasm represent the same entity: a clinicopathologic and molecular genetic study of 23 cases occurring in both men and women at diverse locations

10.1016/j.modpat.2023.100246 · 2023 · External reference

Expanding the clinicopathologic and molecular spectrum of lipoblastoma-like tumor in a series of 28 cases

10.1016/j.modpat.2023.100252 · 2023 · External reference

Lipoblastoma-like tumor of the vulva: further characterization in 8 new cases

10.1097/pas.0000000000000448 · 2015 · External reference

Lipoblastoma-like tumor of the vulva: a clinicopathologic, immunohistochemical, fluorescence in situ hybridization and genomic copy number profiling study of seven cases

10.1038/s41379-018-0102-y · 2018 · External reference

Atypical spindle cell/pleomorphic lipomatous tumour: a clinicopathologic, immunohistochemical and molecular study of 55 cases, highlighting TP53 gene alterations as a genetic hallmark of atypical pleomorphic lipomatous tumour

10.1111/his.15474 · 2025 · External reference

Does “low-grade” dedifferentiated liposarcoma exist? The role of mitotic index in separating dedifferentiated liposarcoma from cellular well-differentiated liposarcoma

10.1097/pas.0000000000002037 · 2023 · External reference

PRRX1-rearranged fibroblastic tumors: a clinicopathologic and molecular study of 18 cases including a novel: PRRX1::EP300 fusion

10.1097/pas.0000000000002472 · 2026 · External reference

PRRX1-rearranged mesenchymal tumor: a case report and review of the literature

10.1177/10935266251374258 · 2025 · External reference

Malignant undifferentiated epithelioid neoplasms with MAML2 rearrangements: a clinicopathologic study of seven cases demonstrating a heterogenous entity

10.1002/gcc.23102 · 2023 · External reference

Recurrent YAP1 and KMT2A gene rearrangements in a subset of MUC4-negative sclerosing epithelioid fibrosarcoma

10.1097/pas.0000000000001382 · 2020 · External reference

Recurrent fusions between YAP1 and KMT2A in morphologically distinct neoplasms within the spectrum of low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma

10.1097/pas.0000000000001423 · 2020 · External reference

YAP1::KMT2A-rearranged sarcomas harbor a unique methylation profile and are distinct from sclerosing epithelioid fibrosarcoma and low-grade fibromyxoid sarcoma

10.1007/s00428-024-03995-2 · 2025 · External reference

Chondroid synoviocytic neoplasm: a clinicopathologic, immunohistochemical, and molecular genetic study of a distinctive tumor of synoviocytes

10.1016/j.modpat.2024.100598 · 2024 · External reference

Pigmented villonodular synovitis with chondroid metaplasia, resembling chondroblastoma of the bone: a report of three cases

10.1038/modpathol.3800770 · 2007 · External reference

Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including FGFR2, FGFR1, MERTK, NTRK1, and TEK: a molecular and clinicopathologic analysis

10.1038/s41379-021-00786-x · 2021 · External reference

Calcified chondroid mesenchymal neoplasm: exploring the morphologic and clinical features of an emergent entity with a series of 33 cases

10.1097/pas.0000000000002044 · 2023 · External reference

Comprehensive molecular characterization of a large series of calcified chondroid mesenchymal neoplasms widening their morphologic spectrum

10.1097/pas.0000000000002260 · 2024 · External reference

Xanthogranulomatous epithelial tumors and keratin-positive giant cell-rich soft tissue tumors: two aspects of a single entity with frequent HMGA2-NCOR2 fusions

10.1038/s41379-022-01115-6 · 2022 · External reference

Xanthogranulomatous epithelial tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women

10.1038/s41379-020-0562-8 · 2020 · External reference

Recurrent novel HMGA2-NCOR2 fusions characterize a subset of keratin-positive giant cell-rich soft tissue tumors

10.1038/s41379-021-00789-8 · 2021 · External reference

Giant cell tumors with HMGA2:: NCOR2 fusion: clinicopathologic, molecular, and epigenetic study of a distinct entity

10.1097/pas.0000000000002051 · 2023 · External reference

SRF fusions other than with RELA expand the molecular definition of SRF-fused perivascular tumors

10.1097/pas.0000000000001546 · 2020 · External reference

Recurrent SRF-RELA fusions define a novel subset of cellular variants in the myofibroma/myopericytoma spectrum: a potential diagnostic pitfall with sarcomas with myogenic differentiation

10.1097/pas.0000000000000811 · 2017 · External reference

Novel SRF-ICA1L fusions in cellular myoid neoplasms with potential for malignant behavior

10.1097/pas.0000000000001336 · 2020 · External reference

Inflammatory rhabdomyoblastic tumor: clinicopathologic and molecular analysis of 13 cases

10.1016/j.modpat.2023.100359 · 2024 · External reference

Histiocyte-rich rhabdomyoblastic tumor: rhabdomyosarcoma, rhabdomyoma, or rhabdomyoblastic tumor of uncertain malignant potential? A histologically distinctive rhabdomyoblastic tumor in search of a place in the classification of skeletal muscle neoplasms

10.1038/s41379-018-0145-0 · 2019 · External reference

“Inflammatory Leiomyosarcoma” and “Histiocyte-rich Rhabdomyoblastic Tumor”: a clinicopathological, immunohistochemical and genetic study of 13 cases, with a proposal for reclassification as “Inflammatory Rhabdomyoblastic Tumor”

10.1038/s41379-020-00703-8 · 2021 · External reference

Toward a unifying entity that encompasses most, but perhaps not all, inflammatory leiomyosarcomas and histiocyte-rich rhabdomyoblastic tumors

10.1038/s41379-021-00797-8 · 2021 · External reference

MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification

10.1038/s41379-018-0120-9 · 2019 · External reference

Clinicopathologic and molecular genetic features of spindle cell rhabdomyosarcoma harboring ZFP64::NCOA2/3 fusions: a series of 14 cases

10.1016/j.modpat.2025.100906 · 2025 · External reference

Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck

10.1002/gcc.23083 · 2022 · External reference

Fusion-driven spindle cell rhabdomyosarcomas of bone and soft tissue: a clinicopathologic and molecular genetic study of 25 cases

10.1016/j.modpat.2023.100271 · 2023 · External reference

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations

10.1038/ng.2969 · 2014 · External reference

MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes

10.1038/modpathol.2016.144 · 2016 · External reference

The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases

10.1111/his.13819 · 2019 · External reference

Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors

10.1038/modpathol.2012.153 · 2013 · External reference

Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types

10.1097/pas.0b013e3181d6150d · 2010 · External reference

Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation

10.1097/pas.0b013e3182671178 · 2013 · External reference

International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

10.1038/s41574-021-00492-3 · 2021 · External reference

Novel genomic risk stratification model for primary gastrointestinal stromal tumors (GIST) in the adjuvant therapy era

10.1158/1078-0432.ccr-23-1184 · 2023 · External reference

Recurrent SMARCB1 inactivation in epithelioid malignant peripheral nerve sheath tumors

10.1097/pas.0000000000001242 · 2019 · External reference

Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases

10.1097/pas.0000000000000379 · 2015 · External reference

OGT-rearranged acral mesenchymal neoplasms: an emerging entity with an expanding pathologic and molecular spectrum

10.1097/pas.0000000000001679 · 2021 · External reference

Acral fibrochondromyxoid tumor: a clinicopathologic and molecular genetic study of 37 cases

10.1016/j.modpat.2024.100599 · 2024 · External reference

A comprehensive clinicopathologic and molecular reappraisal of GLI1-altered mesenchymal tumors with pooled outcome analysis showing poor survival in GLI1-amplified versus GLI1-rearranged tumors

10.1097/pas.0000000000002272 · 2024 · External reference

A distinct malignant epithelioid neoplasm with GLI1 gene rearrangements, frequent S100 protein expression and metastatic potential: expanding the spectrum of pathologic entities with ACTB1/MALAT1/PTCH1-GLI1 fusions

10.1097/pas.0000000000001010 · 2018 · External reference

GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions

10.1038/s41379-019-0293-x · 2019 · External reference

Superficial neurocristic EWSR1::FLI1 fusion tumor: a distinctive, clinically indolent, S100 protein/SOX10-positive neoplasm

10.1016/j.modpat.2024.100537 · 2024 · External reference

Superficial neurocristic FET::ETS fusion tumor: expanding the clinicopathological and molecular genetic spectrum of a recently described entity

10.1016/j.modpat.2024.100656 · 2025 · External reference

Pseudoendocrine sarcoma: clinicopathologic analysis of 23 cases of a distinctive soft tissue neoplasm with metastatic potential, recurrent: CTNNB1: mutations, and a predilection for truncal locations

10.1097/pas.0000000000001751 · 2022 · External reference

Deciphering pseudoendocrine sarcoma: a clinicopathological, molecular, and epigenetic study suggesting biological links with solid pseudopapillary neoplasm of the pancreas

10.1016/j.modpat.2025.100810 · 2025 · External reference

NUTM1/NUTM2B-rearranged intra-abdominal sarcomas: a distinct entity from sarcomas with ESR1 overexpression as a therapeutic target

10.1016/j.modpat.2025.100816 · 2025 · External reference

Expanding the spectrum of NUTM1-rearranged sarcoma: a clinicopathologic and molecular genetic study of 8 cases

10.1097/pas.0000000000002254 · 2024 · External reference

Cytokeratin-positive malignant tumor in the abdomen with EWSR1/FUS-CREB fusion: a clinicopathologic study of 8 cases

10.1097/pas.0000000000001742 · 2022 · External reference

Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites

10.1007/s00428-024-03917-2 · 2024 · External reference

EWSR1::ATF1 fusions characterize a group of extra-abdominal epithelioid and round cell mesenchymal neoplasms, phenotypically overlapping with sclerosing epithelioid fibrosarcomas, and intra-abdominal FET::CREB fusion neoplasms

10.1007/s00428-024-03879-5 · 2024 · External reference

Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors

10.1097/pas.0000000000001203 · 2019 · External reference

A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes

10.1002/gcc.22671 · 2018 · External reference

Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern

10.1002/gcc.22877 · 2020 · External reference

Updated classification of vascular anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group

2025 · External reference

YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases

10.1038/s41379-021-00879-7 · 2021 · External reference

NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker

10.1038/s41379-020-0542-z · 2020 · External reference

Clinicopathological features of three rare EWSR1::NFATC2 sarcomas of bone and soft tissues

10.1177/10668969241228294 · 2024 · External reference

Bone sarcoma with EWSR1-NFATC2 fusion: sarcoma with varied morphology and amplification of fusion gene distinct from ewing sarcoma

10.1177/1066896919827093 · 2019 · External reference

Conventional primary central chondrosarcoma of the pelvis: prognostic factors and outcome of surgical treatment in 162 patients

10.2106/jbjs.17.00105 · 2018 · External reference

Malignant chondroblastoma: an epigenetically distinct subtype of chondroblastoma with a predilection for the skeletally mature

10.1016/j.modpat.2025.100790 · 2025 · External reference

KRAS mutations in brown tumor of the jaws in hyperparathyroidism

10.1111/jop.13048 · 2020 · External reference

Methylation analysis reveals epigenetic congruence between bone sarcomas with H3-3A mutations and malignant giant cell tumors of bone

10.1016/j.modpat.2025.100763 · 2025 · External reference

Does osteofibrous dysplasia progress to adamantinoma and how should they be treated?

10.1302/0301-620x.99b3.38050 · 2017 · External reference

A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation

10.1038/s41379-019-0323-8 · 2020 · External reference